Scarisbrick J, et al. - Since patients with previously treated mycosis fungoides (MF)/Sezary syndrome (SS) stage IB-IVB who received mogamulizumab (MOGA; Poteligeo®) had significantly prolonged progression-free survival and greater overall response rates (ORR) vs patients on vorinostat (VORI) in the MAVORIC Phase 3 study, researchers in this post-hoc analysis specifically tested the effectiveness and safety of the recently approved MOGA in stage IB/IIA MF patients. In MAVORIC, 372 stage IB-IVB MF/SS patients who were treated with ≥1 prior systemic therapy were randomized to MOGA or oral VORI. Study participants included 85 patients with stage IB/IIA MF. This post-hoc analysis of time to next treatment [defined as time to any therapy excluding topical steroids or focal radiation treatment], ORR, and compartmental response in stage IB/IIA shows significant clinical benefit with MOGA in early stage MF patients previously treated with systemic therapies despite MAVORIC not being powered to determine disease-stage treatment effect.